Ten-Year Outcomes of Operable Solitary Hepatocellular Carcinoma Patients: Impact of Tumor Size Over 6.5 cm and Microvascular Invasion

Recruiting now

Conditions studied: Hepatocellular Carcinoma (HCC), Solitary Mass

In brief

The goal of this study is to evaualte the impact of tumor size and microvascular invasion among patients with solitary hepatocellualr carcinoma and post operation. The main questions it aims to answer are: Does the tumor size have more impact on the survival and recurrence than microvascular invasion among solitary operable hepatocellular carcinoma patients? Researchers will retrospectively analyze the prospectively collected clinical database during January 2022 and December 2019 to see whether tumor size more than 6.5 cm or microvascular invasion. The solitary operable hepatocellular carcinoma patients would be classified based on the status of microvascular invasion and tumor size, and the outcome would be evaluated among different sub-populations of the feasible subjects.

Key facts

Study ID

NCT06628661

Run by

Chang Gung Memorial Hospital

People needed

3000

Starts

2024-09-30

Expected to finish

2024-12-01

Last updated by the study team

2024-11-20

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Operable solitary hepatocellular carcinoma

You may not qualify if…

• Not pT1N0M0 or pT2N0M0
• Missing tumor size
• Errors in survival/recurrence dates or status

Where it is running

• Chang Gung Medical Foundation — Taoyuan, Taiwan (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.